Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

10.1016/S1473-3099(21)00125-0

Saved in:

Bibliographic Details
Main Authors:	Natasha Howard, Ishola, D, Manno, D, Afolabi, MO, Keshinro, B, Bockstal, V, Rogers, B, Owusu-Kyei, K, Serry-Bangura, A, Swaray, I, Lowe, B, Kowuor, D, Baiden, F, Mooney, T, Smout, E, Köhn, B, Otieno, GT, Jusu, M, Foster, J, Samai, M, Deen, GF, Larson, H, Lees, S, Goldstein, N, Gallagher, KE, Gaddah, A, Heerwegh, D, Callendret, B, Luhn, K, Robinson, C, Leyssen, M, Greenwood, B, Douoguih, M, Leigh, B, Watson-Jones, D, Kargbo, M, Bockarie, E, James, NL, Kabbah, A, Kamara, A, Koroma, KH, Langley, SO, William, N, Kessebeh, R, Conteh, L, Allieu, K, Bangura, K, Bangura, MS, Bangura, MA, Jalloh, H, Jalloh, AB, Kamara, I, Kamara, M, Konteh, A, Koroma, S, Marrah, C, Sesay, M, Sesay, MT, Deen, AT, Jalloh, A, Kaimbay, RM, Kain, D, Kamara, EL, Kamara, MP, Kamara, OJ, Kamara, SLM, Kanneh, M, Koroma, AH, Lahai, D, Mansaray, IS, Marah, WS, Massaquoi, MJ, Nabie, A, Saidu, NS, Samai, I, Tengheh, JN, Turay, AS, Fornah, A, Sesay, F, Sow, A, Swaray, E, Mansaray, F, Ade-Cole, T, Bangura, LM, Conteh, ML, Koroma, AM, Koroma, M, Sam, A, Scott, T, Sessie, T, Sunders, JHC, Turay, SIS, Weekes, J, Sheku, M, Gibson, L, Ahamed, I, Allieu, W, Kabba, DU
Other Authors:	DEAN'S OFFICE (SSH SCH OF PUBLIC HEALTH)
Format:	Article
Published:	Elsevier BV 2023
Subjects:	Adult Antibodies, Viral Democratic Republic of the Congo Double-Blind Method Ebola Vaccines Ebolavirus Female Hemorrhagic Fever, Ebola Humans Immunity, Humoral Immunogenicity, Vaccine Male Sierra Leone Vaccination Vaccines, DNA Viral Envelope Proteins Viral Vaccines
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/243189
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-243189
record_format	dspace
spelling	sg-nus-scholar.10635-2431892023-07-18T08:22:34Z Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial Natasha Howard Ishola, D Manno, D Afolabi, MO Keshinro, B Bockstal, V Rogers, B Owusu-Kyei, K Serry-Bangura, A Swaray, I Lowe, B Kowuor, D Baiden, F Mooney, T Smout, E Köhn, B Otieno, GT Jusu, M Foster, J Samai, M Deen, GF Larson, H Lees, S Goldstein, N Gallagher, KE Gaddah, A Heerwegh, D Callendret, B Luhn, K Robinson, C Leyssen, M Greenwood, B Douoguih, M Leigh, B Watson-Jones, D Kargbo, M Bockarie, E James, NL Kabbah, A Kamara, A Koroma, KH Langley, SO William, N Kessebeh, R Conteh, L Allieu, K Bangura, K Bangura, MS Bangura, MA Jalloh, H Jalloh, AB Kamara, I Kamara, M Konteh, A Koroma, S Marrah, C Sesay, M Sesay, MT Deen, AT Jalloh, A Kaimbay, RM Kain, D Kamara, EL Kamara, MP Kamara, OJ Kamara, SLM Kanneh, M Koroma, AH Lahai, D Mansaray, IS Marah, WS Massaquoi, MJ Nabie, A Saidu, NS Samai, I Tengheh, JN Turay, AS Fornah, A Sesay, F Sow, A Swaray, E Mansaray, F Ade-Cole, T Bangura, LM Conteh, ML Koroma, AM Koroma, M Sam, A Scott, T Sessie, T Sunders, JHC Turay, SIS Weekes, J Sheku, M Gibson, L Ahamed, I Allieu, W Kabba, DU DEAN'S OFFICE (SSH SCH OF PUBLIC HEALTH) Adult Antibodies, Viral Democratic Republic of the Congo Double-Blind Method Ebola Vaccines Ebolavirus Female Hemorrhagic Fever, Ebola Humans Immunity, Humoral Immunogenicity, Vaccine Male Sierra Leone Vaccination Vaccines, DNA Viral Envelope Proteins Viral Vaccines 10.1016/S1473-3099(21)00125-0 The Lancet Infectious Diseases 22 1 97-109 2023-07-18T08:17:44Z 2023-07-18T08:17:44Z 2022-01-01 2023-07-18T07:36:18Z Article Natasha Howard, Ishola, D, Manno, D, Afolabi, MO, Keshinro, B, Bockstal, V, Rogers, B, Owusu-Kyei, K, Serry-Bangura, A, Swaray, I, Lowe, B, Kowuor, D, Baiden, F, Mooney, T, Smout, E, Köhn, B, Otieno, GT, Jusu, M, Foster, J, Samai, M, Deen, GF, Larson, H, Lees, S, Goldstein, N, Gallagher, KE, Gaddah, A, Heerwegh, D, Callendret, B, Luhn, K, Robinson, C, Leyssen, M, Greenwood, B, Douoguih, M, Leigh, B, Watson-Jones, D, Kargbo, M, Bockarie, E, James, NL, Kabbah, A, Kamara, A, Koroma, KH, Langley, SO, William, N, Kessebeh, R, Conteh, L, Allieu, K, Bangura, K, Bangura, MS, Bangura, MA, Jalloh, H, Jalloh, AB, Kamara, I, Kamara, M, Konteh, A, Koroma, S, Marrah, C, Sesay, M, Sesay, MT, Deen, AT, Jalloh, A, Kaimbay, RM, Kain, D, Kamara, EL, Kamara, MP, Kamara, OJ, Kamara, SLM, Kanneh, M, Koroma, AH, Lahai, D, Mansaray, IS, Marah, WS, Massaquoi, MJ, Nabie, A, Saidu, NS, Samai, I, Tengheh, JN, Turay, AS, Fornah, A, Sesay, F, Sow, A, Swaray, E, Mansaray, F, Ade-Cole, T, Bangura, LM, Conteh, ML, Koroma, AM, Koroma, M, Sam, A, Scott, T, Sessie, T, Sunders, JHC, Turay, SIS, Weekes, J, Sheku, M, Gibson, L, Ahamed, I, Allieu, W, Kabba, DU (2022-01-01). Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. The Lancet Infectious Diseases 22 (1) : 97-109. ScholarBank@NUS Repository. https://doi.org/10.1016/S1473-3099(21)00125-0 1473-3099 1474-4457 https://scholarbank.nus.edu.sg/handle/10635/243189 Elsevier BV Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	Adult Antibodies, Viral Democratic Republic of the Congo Double-Blind Method Ebola Vaccines Ebolavirus Female Hemorrhagic Fever, Ebola Humans Immunity, Humoral Immunogenicity, Vaccine Male Sierra Leone Vaccination Vaccines, DNA Viral Envelope Proteins Viral Vaccines
spellingShingle	Adult Antibodies, Viral Democratic Republic of the Congo Double-Blind Method Ebola Vaccines Ebolavirus Female Hemorrhagic Fever, Ebola Humans Immunity, Humoral Immunogenicity, Vaccine Male Sierra Leone Vaccination Vaccines, DNA Viral Envelope Proteins Viral Vaccines Natasha Howard Ishola, D Manno, D Afolabi, MO Keshinro, B Bockstal, V Rogers, B Owusu-Kyei, K Serry-Bangura, A Swaray, I Lowe, B Kowuor, D Baiden, F Mooney, T Smout, E Köhn, B Otieno, GT Jusu, M Foster, J Samai, M Deen, GF Larson, H Lees, S Goldstein, N Gallagher, KE Gaddah, A Heerwegh, D Callendret, B Luhn, K Robinson, C Leyssen, M Greenwood, B Douoguih, M Leigh, B Watson-Jones, D Kargbo, M Bockarie, E James, NL Kabbah, A Kamara, A Koroma, KH Langley, SO William, N Kessebeh, R Conteh, L Allieu, K Bangura, K Bangura, MS Bangura, MA Jalloh, H Jalloh, AB Kamara, I Kamara, M Konteh, A Koroma, S Marrah, C Sesay, M Sesay, MT Deen, AT Jalloh, A Kaimbay, RM Kain, D Kamara, EL Kamara, MP Kamara, OJ Kamara, SLM Kanneh, M Koroma, AH Lahai, D Mansaray, IS Marah, WS Massaquoi, MJ Nabie, A Saidu, NS Samai, I Tengheh, JN Turay, AS Fornah, A Sesay, F Sow, A Swaray, E Mansaray, F Ade-Cole, T Bangura, LM Conteh, ML Koroma, AM Koroma, M Sam, A Scott, T Sessie, T Sunders, JHC Turay, SIS Weekes, J Sheku, M Gibson, L Ahamed, I Allieu, W Kabba, DU Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
description	10.1016/S1473-3099(21)00125-0
author2	DEAN'S OFFICE (SSH SCH OF PUBLIC HEALTH)
author_facet	DEAN'S OFFICE (SSH SCH OF PUBLIC HEALTH) Natasha Howard Ishola, D Manno, D Afolabi, MO Keshinro, B Bockstal, V Rogers, B Owusu-Kyei, K Serry-Bangura, A Swaray, I Lowe, B Kowuor, D Baiden, F Mooney, T Smout, E Köhn, B Otieno, GT Jusu, M Foster, J Samai, M Deen, GF Larson, H Lees, S Goldstein, N Gallagher, KE Gaddah, A Heerwegh, D Callendret, B Luhn, K Robinson, C Leyssen, M Greenwood, B Douoguih, M Leigh, B Watson-Jones, D Kargbo, M Bockarie, E James, NL Kabbah, A Kamara, A Koroma, KH Langley, SO William, N Kessebeh, R Conteh, L Allieu, K Bangura, K Bangura, MS Bangura, MA Jalloh, H Jalloh, AB Kamara, I Kamara, M Konteh, A Koroma, S Marrah, C Sesay, M Sesay, MT Deen, AT Jalloh, A Kaimbay, RM Kain, D Kamara, EL Kamara, MP Kamara, OJ Kamara, SLM Kanneh, M Koroma, AH Lahai, D Mansaray, IS Marah, WS Massaquoi, MJ Nabie, A Saidu, NS Samai, I Tengheh, JN Turay, AS Fornah, A Sesay, F Sow, A Swaray, E Mansaray, F Ade-Cole, T Bangura, LM Conteh, ML Koroma, AM Koroma, M Sam, A Scott, T Sessie, T Sunders, JHC Turay, SIS Weekes, J Sheku, M Gibson, L Ahamed, I Allieu, W Kabba, DU
format	Article
author	Natasha Howard Ishola, D Manno, D Afolabi, MO Keshinro, B Bockstal, V Rogers, B Owusu-Kyei, K Serry-Bangura, A Swaray, I Lowe, B Kowuor, D Baiden, F Mooney, T Smout, E Köhn, B Otieno, GT Jusu, M Foster, J Samai, M Deen, GF Larson, H Lees, S Goldstein, N Gallagher, KE Gaddah, A Heerwegh, D Callendret, B Luhn, K Robinson, C Leyssen, M Greenwood, B Douoguih, M Leigh, B Watson-Jones, D Kargbo, M Bockarie, E James, NL Kabbah, A Kamara, A Koroma, KH Langley, SO William, N Kessebeh, R Conteh, L Allieu, K Bangura, K Bangura, MS Bangura, MA Jalloh, H Jalloh, AB Kamara, I Kamara, M Konteh, A Koroma, S Marrah, C Sesay, M Sesay, MT Deen, AT Jalloh, A Kaimbay, RM Kain, D Kamara, EL Kamara, MP Kamara, OJ Kamara, SLM Kanneh, M Koroma, AH Lahai, D Mansaray, IS Marah, WS Massaquoi, MJ Nabie, A Saidu, NS Samai, I Tengheh, JN Turay, AS Fornah, A Sesay, F Sow, A Swaray, E Mansaray, F Ade-Cole, T Bangura, LM Conteh, ML Koroma, AM Koroma, M Sam, A Scott, T Sessie, T Sunders, JHC Turay, SIS Weekes, J Sheku, M Gibson, L Ahamed, I Allieu, W Kabba, DU
author_sort	Natasha Howard
title	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
title_short	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
title_full	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
title_fullStr	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
title_full_unstemmed	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
title_sort	safety and long-term immunogenicity of the two-dose heterologous ad26.zebov and mva-bn-filo ebola vaccine regimen in adults in sierra leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
publisher	Elsevier BV
publishDate	2023
url	https://scholarbank.nus.edu.sg/handle/10635/243189
_version_	1772825050549846016

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

Similar Items